Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

An annual jab to protect against HIV “shows potential”, according to an early study. Millions of people around the world are ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Switching to long-acting ART from oral treatments was cost effective for postpartum women with HIV and improved infant outcomes, researchers said at the Conference on Retroviruses and Opportunistic ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from the HPTN 094 (“INTEGRA”) study at the 2025 ...

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...